Karyopharm Therapeutics Inc. (KPTI): Price and Financial Metrics

Karyopharm Therapeutics Inc. (KPTI): $5.37

0.41 (+8.27%)

POWR Rating

Component Grades














  • Growth is the dimension where KPTI ranks best; there it ranks ahead of 92.59% of US stocks.
  • The strongest trend for KPTI is in Value, which has been heading up over the past 179 days.
  • KPTI ranks lowest in Stability; there it ranks in the 0th percentile.

KPTI Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for KPTI is -2.63 -- better than merely 2.98% of US stocks.
  • KPTI's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.14% of US stocks.
  • Revenue growth over the past 12 months for Karyopharm Therapeutics Inc comes in at 94.12%, a number that bests 91.35% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Karyopharm Therapeutics Inc, a group of peers worth examining would be BYSI, INSM, ALBO, INFN, and RDUS.
  • Visit KPTI's SEC page to see the company's official filings. To visit the company's web site, go to www.karyopharm.com.

KPTI Valuation Summary

  • In comparison to the median Healthcare stock, KPTI's EV/EBIT ratio is 108.87% lower, now standing at -2.6.
  • KPTI's EV/EBIT ratio has moved up 18.3 over the prior 95 months.
  • Over the past 95 months, KPTI's price/sales ratio has gone down 1018.6.

Below are key valuation metrics over time for KPTI.

Stock Date P/S P/B P/E EV/EBIT
KPTI 2021-08-31 4.3 -5.3 -2.1 -2.6
KPTI 2021-08-30 4.0 -5.0 -2.0 -2.5
KPTI 2021-08-27 4.1 -5.1 -2.0 -2.5
KPTI 2021-08-26 3.8 -4.6 -1.9 -2.3
KPTI 2021-08-25 3.8 -4.7 -1.9 -2.4
KPTI 2021-08-24 3.7 -4.6 -1.8 -2.3

KPTI Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -56.38%.
  • Its year over year net income to common stockholders growth rate is now at -7.72%.
  • Its 5 year net cashflow from operations growth rate is now at -74.5%.
KPTI's revenue has moved up $209,701,000 over the prior 52 months.

The table below shows KPTI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 209.819 -107.116 -124.088
2021-09-30 118.65 -163.225 -206.229
2021-06-30 102.294 -183.582 -207.912
2021-03-31 113.207 -168.111 -200.756
2020-12-31 108.085 -160.234 -196.273
2020-09-30 91.081 -169.089 -201.499

KPTI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KPTI has a Quality Grade of C, ranking ahead of 58.11% of graded US stocks.
  • KPTI's asset turnover comes in at 0.338 -- ranking 138th of 681 Pharmaceutical Products stocks.
  • CAPR, DRNA, and PLXP are the stocks whose asset turnover ratios are most correlated with KPTI.

The table below shows KPTI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.338 0.965 -0.614
2021-03-31 0.347 0.975 -0.545
2020-12-31 0.299 0.975 -0.534
2020-09-30 0.255 0.967 -0.576
2020-06-30 0.239 0.956 -0.607
2020-03-31 0.189 0.945 -0.671

KPTI Price Target

For more insight on analysts targets of KPTI, see our KPTI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.22 Average Broker Recommendation 1.6 (Moderate Buy)

KPTI Stock Price Chart Interactive Chart >

Price chart for KPTI

KPTI Price/Volume Stats

Current price $5.37 52-week high $14.73
Prev. close $4.96 52-week low $4.00
Day low $5.00 Volume 748,653
Day high $5.45 Avg. volume 2,918,985
50-day MA $4.93 Dividend yield N/A
200-day MA $6.81 Market Cap 428.56M

Karyopharm Therapeutics Inc. (KPTI) Company Bio

Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts.

KPTI Latest News Stream

Event/Time News Detail
Loading, please wait...

KPTI Latest Social Stream

Loading social stream, please wait...

View Full KPTI Social Stream

Latest KPTI News From Around the Web

Below are the latest news stories about Karyopharm Therapeutics Inc that investors may wish to consider to help them evaluate KPTI as an investment opportunity.

The Petri Dish: Moderna, Thermo become long-term partners; Karyopharm medical chief departs

The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.

Yahoo | February 24, 2022

HOOKIPA, Nuvectis top healthcare gainers; Allarity, Homology Medicines lead losers' pack

Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +18%. Nuvectis Pharma (NASDAQ:NVCT) +16%. Ocugen (NASDAQ:OCGN) +14%. Privia Health (NASDAQ:PRVA) +12%. IMARA (NASDAQ:IMRA) +11%. Losers: Allarity Therapeutics (NASDAQ:ALLR) -29%. Homology Medicines (NASDAQ:FIXX) -27%. Karyopharm Therapeutics (NASDAQ:KPTI) -25%. Modular Medical (NASDAQ:MODD) -14%. Mainz Biomed (NASDAQ:MYNZ) -11%....

Seeking Alpha | February 22, 2022

Why Are Karyopharm Shares Plunging Today?

Karyopharm Therapeutics Inc (NASDAQ: KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities." While CEO Paulson looks for Shah's replacement, he has recruited two Big Pharma vets to take up key posts on the team: Patricia Judson, who led women's oncology at GlaxoSmithKline and AstraZeneca, will become the SVP of medical strategy. From AbbVie, Amgen, and Eli Lilly, Stuart Poulton has been appointed SVP of strategy and portfo

Yahoo | February 22, 2022

Here's Why Karyopharm Therapeutics Is Sliding on Tuesday

Investors aren't pleased with the surprise departure of the company's chief medical officer.

Yahoo | February 22, 2022

Karyopharm Announces Changes to Its Clinical Leadership Team

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, b

Yahoo | February 22, 2022

Read More 'KPTI' Stories Here

KPTI Price Returns

1-mo 7.40%
3-mo 0.56%
6-mo -47.46%
1-year 11.41%
3-year -39.32%
5-year -37.19%
YTD -16.49%
2021 -58.46%
2020 -19.25%
2019 104.59%
2018 -2.40%
2017 2.13%

Continue Researching KPTI

Want to see what other sources are saying about Karyopharm Therapeutics Inc's financials and stock price? Try the links below:

Karyopharm Therapeutics Inc (KPTI) Stock Price | Nasdaq
Karyopharm Therapeutics Inc (KPTI) Stock Quote, History and News - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4754 seconds.